Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02486718 · OUTCOME

Maximum Plasma Concentration (Cmax) of Atezolizumab

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] · Source last updated 2026-07-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
micrograms/millilitres (μg/ml)
Interval / dispersion
Geometric Coefficient of Variation
Time frame
30 min post-infusion on Day 1 of Cycle 1 (Cycle length = 21 days)

Analysis population: PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Overall number analyzed is the number of participants with data available for analysis.

Groups in this outcome

Atezolizumab

Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab451

Reported measurements

Source class 1
Values in micrograms/millilitres (μg/ml) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Atezolizumab367124Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        124
        value
        367
denoms
  1. counts
    1. group Id
      OG000
      value
      451
    units
    Participants
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.
    id
    OG000
    title
    Atezolizumab
param Type
GEOMETRIC_MEAN
population Description
PK-evaluable population was defined as all randomized participants who received any dose of the study treatment and who have evaluable pharmacokinetic samples. Overall number analyzed is the number of participants with data available for analysis.
reporting Status
POSTED
time Frame
30 min post-infusion on Day 1 of Cycle 1 (Cycle length = 21 days)
title
Maximum Plasma Concentration (Cmax) of Atezolizumab
type
SECONDARY
unit Of Measure
micrograms/millilitres (μg/ml)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice